Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Accounts Payables (2016 - 2026)

Phibro Animal Health has reported Accounts Payables over the past 13 years, most recently at $133.3 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 34.04% year-over-year to $133.3 million; the TTM value through Dec 2025 reached $133.3 million, up 34.04%, while the annual FY2025 figure was $138.2 million, 61.51% up from the prior year.
  • Accounts Payables for Q4 2025 was $133.3 million at Phibro Animal Health, up from $130.6 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $138.2 million in Q2 2025 and troughed at $62.8 million in Q1 2021.
  • A 5-year average of $91.7 million and a median of $86.0 million in 2023 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: decreased 22.74% in 2023 and later soared 61.51% in 2025.
  • Year by year, Accounts Payables stood at $80.7 million in 2021, then dropped by 0.22% to $80.5 million in 2022, then rose by 7.36% to $86.4 million in 2023, then grew by 15.09% to $99.4 million in 2024, then soared by 34.04% to $133.3 million in 2025.
  • Business Quant data shows Accounts Payables for PAHC at $133.3 million in Q4 2025, $130.6 million in Q3 2025, and $138.2 million in Q2 2025.